| A global systematic review of hepatitis C elimination efforts through micro-elimination JV Lazarus, CA Picchio, CJ Byrne, J Crespo, M Colombo, GS Cooke, ... Seminars in Liver Disease 42 (02), 159-172, 2022 | 30 | 2022 |
| Real‐world outcomes of rapid regional hepatitis c virus treatment scale‐up among people who inject drugs in Tayside, Scotland CJ Byrne, L Beer, SK Inglis, E Robinson, A Radley, DJ Goldberg, ... Alimentary pharmacology & therapeutics 55 (5), 568-579, 2022 | 19 | 2022 |
| Reaching mEthadone users Attending Community pHarmacies with HCV: an international cluster randomised controlled trial protocol (REACH HCV) C Byrne, A Radley, SK Inglis, LJZ Beer, N Palmer, MD Pham, B Healy, ... BMJ open 10 (8), e036501, 2020 | 16 | 2020 |
| Randomised controlled trial conducted in injecting equipment provision sites to compare the effectiveness of different hepatitis C treatment regimens in people who inject drugs … SK Inglis, LJZ Beer, C Byrne, A Malaguti, E Robinson, C Sharkey, ... BMJ open 9 (8), e029516, 2019 | 14 | 2019 |
| Toward microelimination of hepatitis C and HIV coinfection in NHS Tayside, Scotland: Real‐world outcomes C Byrne, E Robinson, N Rae, JF Dillon Health Science Reports 3 (4), e191, 2020 | 13 | 2020 |
| Reaching people receiving opioid agonist therapy at community pharmacies with hepatitis C virus: An international randomised controlled trial CJ Byrne, A Radley, SK Inglis, L Beer, N Palmer, M Duc Pham, K Allardice, ... Alimentary Pharmacology & Therapeutics 55 (12), 1512-1523, 2022 | 11 | 2022 |
| Randomized clinical trial: Direct‐acting antivirals as treatment for hepatitis C in people who inject drugs: Delivered in needle and syringe programs via directly observed … L Beer, S Inglis, A Malaguti, C Byrne, C Sharkey, E Robinson, K Gillings, ... Journal of Viral Hepatitis 29 (8), 646-653, 2022 | 10 | 2022 |
| Increased risk of chronic kidney disease and mortality in a cohort of people diagnosed with metabolic dysfunction associated steatotic liver disease with hepatic fibrosis M Gurun, P Brennan, S Handjiev, A Khatib, D Leith, JF Dillon, CJ Byrne Plos one 19 (4), e0299507, 2024 | 7 | 2024 |
| Laying the foundations for hepatitis C elimination: evaluating the development and contribution of community care pathways to diagnostic efforts E Robinson, CJ Byrne, J Carberry, A Radley, LJ Beer, SK Inglis, J Tait, ... BMC Public Health 23 (1), 54, 2023 | 5 | 2023 |
| Long-term risk factors for developing Barrett’s oesophagus in patients with gastro-oesophageal reflux disease: a longitudinal cohort study CJ Byrne, P Brennan, J Carberry, J Cotton, JF Dillon BMJ Open Gastroenterology 11 (1), e001307, 2024 | 4 | 2024 |
| Viral hepatitis testing and treatment in community pharmacies: a systematic review and meta-analysis MJ Hayes, E Beavon, MW Traeger, JF Dillon, A Radley, S Nielsen, ... eClinicalMedicine 69, 2024 | 4 | 2024 |
| A narrative review of lifestyle management guidelines for metabolic dysfunction-associated steatotic liver disease DI Wajcman, CJ Byrne, JF Dillon, PN Brennan, M Villota-Rivas, ... Hepatology, 10.1097, 2024 | 3 | 2024 |
| Psychosocial factors associated with overdose subsequent to Illicit Drug use: a systematic review and narrative synthesis CJ Byrne, F Sani, D Thain, EH Fletcher, A Malaguti Harm reduction journal 21 (1), 81, 2024 | 3 | 2024 |
| Drug network identification predicts injecting risk behavior among people who inject drugs on hepatitis C virus treatment in Tayside, Scotland A Malaguti, CJ Byrne, F Sani, K Power, A Eriksen, JF Dillon Behavioral Medicine 50 (2), 130-140, 2024 | 3 | 2024 |
| Mixed-methods evaluation of point-of-care hepatitis C virus RNA testing in a Scottish prison CJ Byrne, A Malaguti, SK Inglis, JF Dillon BMJ open 13 (4), e068604, 2023 | 3 | 2023 |
| Optimal ALT threshold for the automated diagnosis of MASLD: A population-based study using iLFT J Lee, CJ Byrne, PN Brennan, I MacPherson, E Dow, JF Dillon Annals of Hepatology 29 (2), 101280, 2024 | 2 | 2024 |
| A multicomponent holistic care pathway for people who use drugs in Tayside, Scotland CJ Byrne, A Radley, E Fletcher, D Thain, BP Stephens, JF Dillon International Journal of Drug Policy 120, 104159, 2023 | 2 | 2023 |
| Decentralisation of hepatitis C virus care into community settings: A key approach on the path to elimination PN Brennan, CJ Byrne, JF Dillon Liver International 42 (6), 1222-1224, 2022 | 2 | 2022 |
| ‘It was like coming back from the clouds’: a qualitative analysis of the lived experience of overdose consequent to drug use among a cohort of people who use drugs in Scotland CJ Byrne, F Sani, T Flynn, A Malaguti Harm Reduction Journal 21 (1), 112, 2024 | | 2024 |
| P4 Fibrosis associated with increased likelihood of chronic kidney disease among people diagnosed with non-alcoholic fatty liver disease in Tayside, Scotland M Gurun, CJ Byrne, P Brennan, JF Dillon Gut 72 (Suppl 2), A48-A48, 2023 | | 2023 |
John DillonProfessor University of DundeeBestätigte E-Mail-Adresse bei dundee.ac.uk